HRAS Q61R

CI-VAR-00003575Explore in graph →CIViC 1391

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
HRAS Q61L OR HRAS Q61R OR HRAS G12V	Binimetinib + Everolimus + Mirdametinib + MTOR Kinase Inhibitor AZD8055 + SelumetinibSubstitutes	Predictive	D	Supports Sensitivity Response	3	accepted	EID700 In preclinical cancer cell line and Ba/F3 models, HRAS Q61L, Q61R, and G12V mutations conferred sensitivity to MEK inhibitors (AZD6244/selumetinib, MEK162/binimetinib, and PD0325901) and mTOR inhibito… (full text at CIViC) PMID 26544513 · Kiessling et al., 2015 · Open in CIViC	civic
Skin Squamous Cell Carcinoma1
HRAS Q61R	Vemurafenib	Predictive	C	Supports Resistance	—	submitted

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.